Digestive Diseases and Sciences

, Volume 52, Issue 1, pp 78–83 | Cite as

The Effect of Oral α-Galactosidase on Intestinal Gas Production and Gas-Related Symptoms

  • Michele Di Stefano
  • Emanuela Miceli
  • Samantha Gotti
  • Antonio Missanelli
  • Samanta Mazzocchi
  • Gino Roberto CorazzaEmail author
Original Paper


Bloating, abdominal distention, and flatulence represent very frequent complaints in functional disorders but their pathophysiology and treatment are largely unknown. Patients frequently associate these symptoms with excessive intestinal gas and the reduction of gas production may represent an effective strategy. The aim was to evaluate the effect of α-galactosidase administration, in a randomized double-blind placebo-controlled protocol, on intestinal gas production and gas-related symptoms after a challenge test meal in healthy volunteers. Eight healthy volunteers ingested 300 or 1200 GalU of α-galactosidase or placebo during a test meal containing 420 g of cooked beans. Breath hydrogen excretion and occurrence of bloating, abdominal pain, discomfort, flatulence, and diarrhea were measured for 8 hr. The administration of 1200 GalU of α-galactosidase induced a significant reduction of both breath hydrogen excretion and severity of flatulence. A reduction in severity was apparent for all considered symptoms, but both 300 and 1200 GalU induced a significant reduction in the total symptom score. α-Galactosidase reduced gas production following a meal rich in fermentable carbohydrates and may be helpful in patients with gas-related symptoms.


Bloating Functional bowel disorders α-Galactosidase Intestinal gas production Colonic fermentation 


  1. 1.
    Thomson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA (1999) Functional bowel disorders and functional abdominal pain. Gut 45(Suppl II):II43–II47CrossRefGoogle Scholar
  2. 2.
    Johnsen R, Jacobsen BK, Forde OH (1986) Association between symptoms of irritable colon and psychological and social conditions and lifestyle. BMJ 292:1633–1635PubMedGoogle Scholar
  3. 3.
    Kay L, Jorgensen T, Jensen KH (1994) The epidemiology of irritable bowel syndrome in a random population. Prevalence, incidence, natural history and risk factors. J Intern Med 236:23–30PubMedCrossRefGoogle Scholar
  4. 4.
    Strocchi A, Levitt D (1993) Intestinal gas. In: Sleisenger MH, Fordtran JS (eds) Gastrointestinal disease. Philadelphia, Saunders, pp 1035–1042Google Scholar
  5. 5.
    Levitt MD, Furne J, Olsson S (1996) The relation of passage of gas and abdominal bloating to colonic gas production. Ann Intern Med 124:422–424PubMedGoogle Scholar
  6. 6.
    Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza GR (2000) Non-absorbable antibiotics for managing intestinal gas production and gas related symptoms. Aliment Pharmacol Ther 14:1001–1008PubMedCrossRefGoogle Scholar
  7. 7.
    Friis H, Bodè S, Rumessen JJ (1991) Effect of simethicone on lactulose-induced H2 production and gastrointestinal symptoms. Digestion 49:227–230PubMedCrossRefGoogle Scholar
  8. 8.
    Danhof IE, Stavola JJ (1974) Accelerated transit of intestinal gas with simethicone. Obstet Gynecol 44:148–154PubMedGoogle Scholar
  9. 9.
    Hall RG Jr, Thompson H, Strother A (1981) Effects of orally administered activated charcoal on intestinal gas. Am J Gastroenterol 75:192–196PubMedGoogle Scholar
  10. 10.
    Jai NK, Patel VP, Pitchumoni CS (1986) Activated charcoal, simethicone, and intestinal gas: a double-blind study. Ann Intern Med 105:61–62Google Scholar
  11. 11.
    Potter T, Ellis C, Levitt MD (1985) Activated charcoal: in vivo and in vitro studies of effects on gas formation. Gastroenterology 88:620–624PubMedGoogle Scholar
  12. 12.
    White JG, Hightower NC, Riggs M, Dyck WP (1991) Does activated charcoal relieve gas symptoms? A placebo controlled study. Gastroenterology 100:A261Google Scholar
  13. 13.
    Sutalf LO, Levitt MD (1979) Follow-up of a flatulent patient. Dig Dis Sci 24:652–654CrossRefGoogle Scholar
  14. 14.
    Gaon D, Garmendia C, Murrielo NO, et al. (2002) Effect of Lactobacillus strains (L. casei and L. acidophilus strains cereal) on bacterial overgrowth related chronic diarrhea. Medicina (B Aires) 62:159–163Google Scholar
  15. 15.
    Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B (2000) Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95:1231–1238PubMedCrossRefGoogle Scholar
  16. 16.
    O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128:541–551PubMedCrossRefGoogle Scholar
  17. 17.
    Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17:895–904PubMedCrossRefGoogle Scholar
  18. 18.
    Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR (2000) Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 14:551–556PubMedCrossRefGoogle Scholar
  19. 19.
    Corazza GR, Strocchi A, Sorge M, Bentai G, Gasbarrini G (1993) Prevalence and consistency of low breath H2 excretion following lactulose ingestion. Possible implications for the clinical use of the H2 breath test. Dig Dis Sci 38:2010–2016PubMedCrossRefGoogle Scholar
  20. 20.
    Huskinsson EC (1974) Measurement of pain. Lancet 2:1127–1131CrossRefGoogle Scholar
  21. 21.
    Kotler OP, Holt PR, Rosensweig NS (1982) Modification of the breath hydrogen test increased sensitivity for the detection of carbohydrate malabsorption. J Lab Clin Med 100:798–805PubMedGoogle Scholar
  22. 22.
    Thompson DG, O’Brien JD, Hardie JM (1986) Influence of the oropharyngeal microflora on the measurements of exhaled breath hydrogen. Gastroenterology 191:853–860Google Scholar
  23. 23.
    Rosenthal A, Solomons NW (1983) Time-course of cigarette smoke contamination of clinical hydrogen breath-analysis tests. Clin Chem 29:1980–1981PubMedGoogle Scholar
  24. 24.
    Payne DL, Welsh JD, Claypool PL (1983) Breath hydrogen (H2) response to carbohydrate malabsorption after exercise. J Lab Clin Med 102:147–150PubMedGoogle Scholar
  25. 25.
    Kotler OP, Holt PR, Rosensweig NS (1982) Modification of the breath hydrogen test increased sensitivity for the detection of carbohydrate malabsorption. J Lab Clin Med 100:798–805PubMedGoogle Scholar
  26. 26.
    Serra J, Azpiroz F, Malagelada JR (2001) Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 48:14–19PubMedCrossRefGoogle Scholar
  27. 27.
    Serra J, Azpiroz F, Malagelada JR (2001) Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation. Am J Physiol Gastrointest Liver Physiol 281:G138–G143PubMedGoogle Scholar
  28. 28.
    Waye JD, Pitman E, Weiss A, Krueger K (1975) The bubble problem in endoscopy. Gastrointest Endosc 14:34–35Google Scholar
  29. 29.
    Caldarella MP, Serra J, Azpiroz F, Malagelada JR (2002) Prokinetic effects in patients with intestinal gas retention. Gastroenterology 22:1748–1755CrossRefGoogle Scholar
  30. 30.
    Muller–Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, Ruegg P (2001) Tegaserod, a 5HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 15:1655–1666PubMedCrossRefGoogle Scholar
  31. 31.
    Di Stefano M, Missanelli A, Miceli E, Mazzocchi S, Corazza GR (2004) Tegaserod improves abdominal bloating without modifying intestinal gas production capacity. Dig Liv Dis 36:174CrossRefGoogle Scholar
  32. 32.
    Muller-Lissner S, Holtmann G, Rueegg P, Weidinger G, Loffler H (2005) Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 21:11–20PubMedCrossRefGoogle Scholar
  33. 33.
    Gillis JC, Brogden RN (1995) Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49:467–484PubMedGoogle Scholar
  34. 34.
    Attar A, Flourie B, Rambaud JC, Franchisseur C, Ruszniewski P, Bouhnik Y (1999) Antibiotic efficacy in small intestine bacterial overgrowth related chronic diarrhea: a crossover, randomized trial. Gastroenterology 17:794–797CrossRefGoogle Scholar
  35. 35.
    Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO (2002) Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 47:2615–2620PubMedCrossRefGoogle Scholar
  36. 36.
    Castiglione F, Rispo A, Di Girolamo E, et al. (2003) Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 18:1107–1112PubMedCrossRefGoogle Scholar
  37. 37.
    Di Stefano M, Miceli E, Missanelli A, Mazzocchi S, Corazza GR (2005) Absorbable versus non-absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind-loop syndrome. Aliment Pharmacol Ther 21:985–992PubMedCrossRefGoogle Scholar
  38. 38.
    Lettieri JT, Dain B (1998) Effect of beano on the tolerability and pharmacodynamics of acarbose. Clin Ther 20:497–504PubMedCrossRefGoogle Scholar
  39. 39.
    Solomons NW, Guerrero AM, Zepeda E, Grazioso C (1991) The efficacy of an oral α-galactosidase to promote oligosaccaride hydrolysis and to reduce intolerance symptom after ingestion of beans: a dose response trial. Am J Clin Nutr 53:P28Google Scholar
  40. 40.
    Ganiats TG, Norcross WA, Halverson AL, Burford PA, Palinkas LA (1994) Does beano prevent gas? A double blind crossover study of oral α-galactosidase to treat dietary oligosaccharide intolerance. J Fam Pract 39:441–445PubMedGoogle Scholar
  41. 41.
    Kellow JE, Phillips SF (1987) Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 92:1885–1893PubMedGoogle Scholar
  42. 42.
    Whitehead WE, Holtkotter B, Enck P, Hoelzl R, Holmes KD, Anthony J, Shabsin HS, Schuster MM (1990) Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 98:1187–1192PubMedGoogle Scholar
  43. 43.
    Mayer EA, Gebhart GF (1994) Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 107:271–293PubMedGoogle Scholar
  44. 44.
    Swarbrick ET, Hegarty JE, Bat L, Williams CB, Dawson AM (1980) Site of pain from the irritable bowel. Lancet 2:443–446PubMedCrossRefGoogle Scholar
  45. 45.
    Moriarty KJ, Dawson AM (1982) Functional abdominal pain: further evidence that whole gut is affected. BMJ 284:1670–1672PubMedCrossRefGoogle Scholar
  46. 46.
    Mearin F, Cucala M, Azpiroz F, Malagelada JR (1991) The origin of symptoms on the brain–gut axis in functional dyspepsia. Gastroenterology 101:999–1006PubMedGoogle Scholar
  47. 47.
    Silverman DH, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA (1997) Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 112:64–72PubMedCrossRefGoogle Scholar
  48. 48.
    Aggarwal A, Cutts TF, Abell TL, Cardoso S, Familoni B, Bremer J, Karas J (1994) Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology 106:945–950PubMedGoogle Scholar
  49. 49.
    Spiller RC, Brown ML, Phillips SF (1986) Decreased fluid tolerance, accelerated transit, and abnormal motility of the human colon induced by oleic acid. Gastroenterology 91:100–107PubMedGoogle Scholar
  50. 50.
    Kamath PS, Hoepfner MT, Phillips SF (1987) Short-chain fatty acids stimulate motility of the canine ileum. Am J Physiol 253(4; Pt 1):G427–G433PubMedGoogle Scholar
  51. 51.
    Corsetti M, Gevers AM, Caenepeel P, Tack J (2004) The role of tension receptors in colonic mechanosensitivity in humans. Gut 53:1787–1793PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Michele Di Stefano
    • 1
  • Emanuela Miceli
    • 1
  • Samantha Gotti
    • 2
  • Antonio Missanelli
    • 1
  • Samanta Mazzocchi
    • 1
  • Gino Roberto Corazza
    • 1
    Email author
  1. 1.I° Department of Medicine, IRCCS “S. Matteo” HospitalUniversity of PaviaPaviaItaly
  2. 2.Promefarm SRLMilanoItaly

Personalised recommendations